News

Feb, 2021

News / Media

Feb 26, 2021

Notice Regarding Continuation of the Performance-linked Stock Compensation Scheme and Performance-linked Stock Delivery Scheme for the Domestic and Global Astellas Group Executives

News / Media

Feb 19, 2021

Astellas Announces Positive Topline Results from Two Phase 3 Pivotal Global Trials of Fezolinetant for the Nonhormonal Treatment of Vasomotor Symptoms in Postmenopausal Women

TOKYO, February 19, 2021 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced positive topline results from the Phase 3 pivotal SKYLIGHT 1™ and SKYLIGHT 2™ clinical trials for fezolinetant, an investigational oral, nonhormonal compound being studied for the treatment of moderate to severe vasomotor symptoms (VMS) – i.e., hot flashes associated...

News / Media

Feb 19, 2021

Astellas and Seagen Announce Submission of Two Supplemental Biologics License Applications to the U.S. FDA for PADCEV^® (enfortumab vedotin-ejfv) in Locally Advanced or Metastatic Urothelial Cancer

- Submissions will be Reviewed Under Real-Time Oncology Review Based on Clinical Trials EV-301 and Cohort 2 of EV-201 - TOKYO and BOTHELL, Wash. – Feb. 18, 2021 -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Seagen Inc. (Nasdaq:SGEN) today announced completion of submissions for two supplemental Biologics License Applications (sBLAs) to the U.S. Food...

News / Media

Feb 15, 2021

Astellas and Seagen Announce Phase 3 Trial Results Demonstrating Survival Advantage of PADCEV^® (enfortumab vedotin-ejfv) in Patients with Previously Treated Advanced Urothelial Cancer

- Findings from the EV-301 Trial Showed Significant Improvements in Overall Survival and Progression-Free Survival Compared to Chemotherapy - - EV-301 Intended to Support Global Registrations, Convert Accelerated to Regular Approval in U.S. - - Data Published in the New England Journal of Medicine, Presented at the 2021 ASCO Genitourinary Cancers Symposium - TOKYO and BOTHELL, Wash. – February 12...

News / Media

Feb 15, 2021

Astellas and Seagen Announce Presentation of Results from PADCEV^® (enfortumab vedotin-ejfv) Pivotal Trial in Patients with Previously Treated Advanced Urothelial Cancer Who Were Ineligible for Cisplatin Chemotherapy

- Durable Tumor Responses Experienced Among Patients Previously Treated with Immunotherapy in Second Cohort of EV-201 Trial - - Data Presented in Oral Presentation at the 2021 ASCO Genitourinary Cancers Symposium - TOKYO and BOTHELL, Wash. – February 12, 2021 -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Seagen Inc. (Nasdaq:SGEN) today announced...

Jan, 2021

News / IR

Jan 29, 2021

Posted Financial Results for 3Q/FY2020

Dec, 2020

News / IR

Dec 10, 2020

Updated “R&D Meeting” Section

Oct, 2020

News / IR

Oct 30, 2020

Posted Financial Results for 2Q/FY2020

Sep, 2020

News / IR

Sep 30, 2020

Annual Report 2020 is now available.

Astellas publish its annual report as an integrated report to enable deeper stakeholder understanding of Astellas' efforts to continuously create value for sustainable growth. Annual Report 2020 is now available at the following link: https://www.astellas.com/en/investors/annual-report In order to provide timely information, we publish the Annual Report on the web site. The information in the...

Aug, 2020

News / IR

Aug 04, 2020

Posted Financial Results for 1Q/FY2020

Nothing Found

Unfortunately, we weren't able to find a match for your search query. Please try again.

Nothing Found

Unfortunately, we weren't able to find a match for your search query. Please try again.